Pharmaceuticals News and Research

RSS

Chindex announces joint venture deal with Fosun Pharma

Chindex International, a leading independent American provider of Western healthcare products and services in the People's Republic of China, and Shanghai Fosun Pharmaceutical, a leading manufacturer and distributor of western and Chinese medicine and devices in China, today announced the formation of the previously-proposed joint venture to independently operate certain combined medical device businesses, including Chindex's Medical Products division.

28 Dec 2010

Intellect obtains pharmacokinetic data from OX1 Phase 1b trial for Alzheimer's disease

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained a draft pharmacokinetic report from its completed Phase 1b trial for its lead Alzheimer's candidate, OX1. The Company previously reported on the safety aspects of the trial, which demonstrated that OX1 is safe and well tolerated at all dose levels tested.

28 Dec 2010

Proellex vaginal delivery exhibits four times activity of oral dose in animal study

Repros Therapeutics Inc. today announced it has completed two animal model studies of the use of Proellex® in a vaginally administered formulation that demonstrated effects on progesterone sensitive tissues equivalent to the highest oral dose formerly in development by the Company.

28 Dec 2010

King Pharmaceuticals resubmits NDA for REMOXY

King Pharmaceuticals®, Inc. and Pain Therapeutics®, Inc. today announced that King has resubmitted a New Drug Application for REMOXY® to the U.S. Food and Drug Administration in response to a Complete Response letter received by Pain Therapeutics in December 2008.

28 Dec 2010

Biglycan protein offers potential therapy for muscular dystrophy

A novel potential therapy based on a natural human protein significantly slows muscle damage and improves function in mice who have the same genetic mutation as boys with the most common form of muscular dystrophy, according to a paper published online Dec. 27 in the Proceedings of the National Academy of Sciences.

28 Dec 2010

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

Vicus Therapeutics, LLC, today announced the initiation of a Phase 2 trial evaluating VT-122, a novel investigational combination of etodolac and propranolol, and Nexavar® (sorafenib) tablets, as a potential new treatment option for patients with advanced liver cancer (hepatocellular carcinoma), systemic inflammation and cachexia.

28 Dec 2010

NDA resubmitted for DURECT's ORADUR technology based REMOXY

DURECT Corporation today reported that King Pharmaceuticals, Inc. and Pain Therapeutics, Inc. have announced that King has resubmitted a New Drug Application (NDA) for REMOXY® to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter received by Pain Therapeutics in December 2008. This is a Class 2 resubmission with a six month review cycle.

28 Dec 2010

Exiqon announces introduction of GLP compliant services for miRNA biomarker screening

Exiqon A/S, a leading provider of technologies for biomarker detection, today announced the introduction of GLP compliant services for miRNA biomarker screening and diagnostic assay development for clinical trials.

27 Dec 2010

Stem cell therapy helps patient with diabetes gangrene recover from foot ulcer: ICMS conference

During ICMS Annual International Congress on Regenerative and Cell Based Medicine Conference held on November 12, 2010 in Las Vegas, Nevada, it was announced that a patient with complications of diabetes gangrene recovered from foot ulcer through stem cell therapy.

27 Dec 2010

AMPK activates autophagy by activating ATG1 enzyme

Researchers at the Salk Institute for Biological Studies have discovered how AMPK, a metabolic master switch that springs into gear when cells run low on energy, revs up a cellular recycling program to free up essential molecular building blocks in times of need.

24 Dec 2010

60% of type 2 diabetics who use insulin would switch to a less expensive biosimilar insulin if available

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 60 percent of surveyed type 2 diabetes patients in the U.S. who currently use insulin indicate they would request that their doctor switch them to a less expensive biosimilar insulin if such an agent became available.

24 Dec 2010

Financial Times examines how Brazil's state-run drug sector is engaging in partnerships at home, abroad

"Dilma Rousseff had barely been confirmed as Brazil's new president in November when she made her first foreign visit, to Mozambique," which "included a symbolic stop-off at a pharmaceutical factory that is under construction in preparation for opening in 2014. … The plant will produce a range of medicines for one of its leading lusophone - Portuguese-speaking - African partners, marking the resurgent power and growing reach of its sponsor, Brazil's own state-led drug sector," the Financial Times writes in an article that examines the partnerships Brazil is establishing at home and abroad.

24 Dec 2010

Teva receives FDA complete response letter for glatiramer acetate 0.5mL injection sNDA

Teva Pharmaceutical Industries Ltd. announced today that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for a lower-volume (0.5mL) injection of glatiramer acetate. Copaxone® containing 20mg of glatiramer acetate in 1ml is the global market leader in the treatment of relapsing-remitting multiple sclerosis (RRMS).

24 Dec 2010

American Regent initiates voluntary recall of Sodium Bicarbonate Injection, USP 7.5% and 8.4%

American Regent is conducting a nationwide voluntary recall to the consumer and user level of ALL unexpired lots of the following products: Sodium Bicarbonate Injection, USP, 7.5%, 44.6 mEq/50 mL, Single Dose Vial

24 Dec 2010

AVMA offers DEA guidance on new controls for propofol

The American Veterinary Medical Association (AVMA) has offered input to help smooth implementation of proposed new federal guidelines on a useful and effective induction agent, propofol.

23 Dec 2010

Target enrollment reached in belinostat Phase 2 study in Carcinoma of Unknown Primary

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, announced today that the target enrollment has been reached for the Phase 2 study of belinostat in Carcinoma of Unknown Primary (CUP).

23 Dec 2010

Janssen files abiraterone acetate NDS with Health Canada for metastatic, advanced prostate cancer

Janssen Inc. has filed a New Drug Submission (NDS) to Health Canada for the investigational drug abiraterone acetate administered with prednisone for the treatment of metastatic, advanced prostate cancer in patients who have received prior chemotherapy containing a taxane. Submissions for abiraterone acetate have also been filed with health authorities in the United States and Europe.

23 Dec 2010

Ventrus closes public offering of common stock

Ventrus Biosciences Inc., a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that it closed its previously announced public offering of 2,900,000 shares of common stock.

23 Dec 2010

Angiotech executes supplement to Subordinated Note Indenture

Angiotech Pharmaceuticals, Inc. today announced that it and U.S. Bank National Association, as successor trustee under the Company's subordinated note indenture, dated as of March 23, 2006, at the direction of a majority of the holders of the Company's 7.75% Senior Subordinated Notes due 2014, have executed a supplement to the Subordinated Note Indenture.

23 Dec 2010

Pfizer's sublicensing of Tanaproget triggers $1 million upfront payment to Ligand

Ligand Pharmaceuticals Incorporated announced today that its partner Pfizer, Inc. has granted a sublicense to a multi-national pharmaceutical company for Tanaproget, also known as NSP-989. As a result, Ligand will receive an upfront payment of $1 million from Pfizer. Ligand is entitled to clinical and regulatory milestone payments from Pfizer as Tanaproget advances through the development process, as well as tiered royalties on net sales.

23 Dec 2010

Pharmaceuticals News and Research

Chindex announces joint venture deal with Fosun Pharma

Intellect obtains pharmacokinetic data from OX1 Phase 1b trial for Alzheimer's disease

Proellex vaginal delivery exhibits four times activity of oral dose in animal study

King Pharmaceuticals resubmits NDA for REMOXY

Biglycan protein offers potential therapy for muscular dystrophy

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

NDA resubmitted for DURECT's ORADUR technology based REMOXY

Exiqon announces introduction of GLP compliant services for miRNA biomarker screening

Stem cell therapy helps patient with diabetes gangrene recover from foot ulcer: ICMS conference

AMPK activates autophagy by activating ATG1 enzyme

60% of type 2 diabetics who use insulin would switch to a less expensive biosimilar insulin if available

Financial Times examines how Brazil's state-run drug sector is engaging in partnerships at home, abroad

Teva receives FDA complete response letter for glatiramer acetate 0.5mL injection sNDA

American Regent initiates voluntary recall of Sodium Bicarbonate Injection, USP 7.5% and 8.4%

AVMA offers DEA guidance on new controls for propofol

Target enrollment reached in belinostat Phase 2 study in Carcinoma of Unknown Primary

Janssen files abiraterone acetate NDS with Health Canada for metastatic, advanced prostate cancer

Ventrus closes public offering of common stock

Angiotech executes supplement to Subordinated Note Indenture

Pfizer's sublicensing of Tanaproget triggers $1 million upfront payment to Ligand

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence